|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 遗传学在胆管细胞癌发展中的重要性显示文摘胆管细胞癌(CCA)是肝脏一种少见的恶性肿瘤,起源于胆管。在过去的30年里,CCA在世界各地的发病率不断的增高,但其预后依然很差,几乎未改变过。尽管已发现几个危险因子与该肿瘤的发生相关,但这些危险因子中没有一个在大多数患者中得以肯定。由于诊断时多已是晚期以及有限的治疗选择,导致CCA生存率很低。近来对CCA遗传学和表观遗传学上变化的研究结果为重新阐明胆管细胞恶性转化的分子学机制带来了希望。沿着这一方向进一步研究将有助于形成新的诊断、预后和治疗方法。该篇全面概述了CCA的最新进展,描述迄今所报道过的发生在CCA中最重要的基因突变和表观遗传学改变。 | Luca Maroni Irene Pierantonelli Jesus M.Banales Antonio Benedetti Marco Marzioni 史肖华 王强凤 | 2015 | 中国普通外科杂志2015，24，2： | 6 |
| 2 | Role of autophagy in cholangiocarcinoma:Pathophysiology and implications for therapy显示文摘Cholangiocarcinoma(CCA)is a malignant tumour of the biliary system that originates from the neoplastic transformation of cholangiocytes.CCA is characterized by late diagnosis and poor outcome,with surgery considered as the last option for management.Autophagy is a physiological lysosomal degradation process,essential for cellular homeostasis and ubiquitous in all eukaryotic cells.Several studies have reported a potential involvement of autophagy in cancer,but it remains unclear whether activation of this process represents a survival mechanism of cancer cells.In the present review,we examine the autophagic process and summarize the current knowledge about the involvement of autophagy in the progression of cancer.The link between autophagy and chemoresistance and the use of autophagic markers in diagnosis are also considered in detail.Preliminary evidence shows that the combination of autophagy modulators(activators or inhibitors)with conventional chemotherapeutic agents offers a possible treatment option against signalling pathways that are hyperactivated or altered in CCA.In vitro evidence suggests that combination of chemotherapy agents,such as cisplatin,under activation or inhibition of autophagic processes,in two different CCA cell lines,may improve chemosensitivity and reduce cell survival,respectively.A deeper understanding of these pathways,in both cancer and non-cancer cells,could unveil possible therapeutic targets to treat CCA patients. | Elisabetta Ninfole Claudio Pinto Antonio Benedetti Marco Marzioni Luca Maroni | 2021 | World Journal of Clinical Cases2021，9，22： | 3 |
| 3 | Dupilumab治疗常年性变应性鼻炎并发哮喘患者的疗效和安全性显示文摘背景Dupilumab是一种抗IL-4受体α亚基的抗体,可以阻断IL-4/IL-13的信号转导。IL-4/IL-13是2型/Th2型免疫疾病(如特应性/过敏性疾病)的关键驱动因子。一项重要的2b期临床研究(NCT01854047)显示,在使用了中高剂量吸入激素联合长效β2受体激动剂(ICS/LABA)后仍控制不佳的持续性哮喘患者中,dupilumab可减少哮喘重度急性发作,改善患者的肺功能和生活质量,且耐受性良好。目的探讨在哮喘并发常年性变应性鼻炎(PAR)患者中,dupilumab对SNOT-22的总分及其中变应性鼻炎(AR)相关症状评分的影响。方法对2b临床研究中每2周(q2w) 200 mg和300 mg dupilumab治疗后的数据进行析因分析。这两种剂量的dupilumab目前正在3期临床研究(NCT02414854)中进行验证。PAR定义为:在研究开始时,患者出现对典型的常年性抗原产生特异性应答(Ig E≥0. 35 Ku/L)。结果总共241例(61%)患者患有PAR。与安慰剂相比,每两周300 mg dupilumab显著改善了在哮喘并发PAR的患者中SNOT-22的总分(最小二乘平均差,-5. 98; 95%CI,-10. 45~-1. 5; P=0. 009)和4项AR相关症状的评分(鼻塞,-0. 60; 95%CI,-0. 96~-0. 25;流鼻涕,-0. 67; 95%CI,-1. 04~-0. 31;打喷嚏,-0. 55; 95%CI,-0. 89~-0. 21;鼻后分泌物,-0. 49;95%CI,-0. 83~-0. 16; 4项评分都P <0. 01);每两周200 mg dupilumab治疗减少了并发PAR的患者的SNOT-22总分(-1. 82; 95%CI,-6. 46~2. 83; P=0. 443)和AR相关的症状评分,但与安慰剂相比无统计学差异。在无PAR的哮喘患者中,dupilumab与安慰剂治疗这些评分无差异。结论每两周300 mg dupilumab治疗显著改善了在控制不佳的持续性哮喘并发PAR患者中的AR相关的鼻部症状。 | Steven F.Weinstein Rohit Katial Shyamalie Jayawardena Gianluca Pirozzi Heribert Staudinger Laurent Eckert Vijay N.Joish Nikhil Amin Jaman Maroni Paul Rowe Neil M.H.Graham Ariel Teper 黄庭萱(翻译) 刘春涛(审校) | 2018 | 中华临床免疫和变态反应杂志2018，12，5： | 2 |
| 4 | 多绳金刚石串珠锯的技术特点和加工成本分析(二)显示文摘4多绳串珠锯的特点
与砂锯相比,多绳串珠锯有许多的优点,而新型多绳串珠锯所具备的优点和特性,足以取代或对传统砂锯加工花岗石的工艺方法构成极大的竞争。 | PAOLO MARONI 廖原时(编译) | 2008 | 石材2008，，6： | 2 |
| 5 | Lipid targets during statin treat- ment in dyslipidemic patients affected by nonalcoholic fatty liver disease 显示文摘 | Maroni L Guasti L Castiglioni L | 2011 | Am J Med Sci2011，342，5： | 1 |
| 6 | Preparation and evaluation of an oral delivery system for time-dependent colon release of insulin and selected protease inhibitor and absorption enhancer compounds显示文摘 | Curto MDD Maroni A Foppoli A | 2009 | J Pharm Sci2009，98，： | 1 |
| 7 | Film coatings for oral pulsatile release 显示文摘 | Maroni A Zema L Loreti G | 2013 | lnt J Pharm2013，457，2： | 1 |
| 8 | Different HPMC viscosity gardes as coasting agents for all oral time and/or site-controlled dehvery system:Astudy on process parameters and in vitro performances显示文摘 | Sangalli A Maroni A Foppoli | 2004 | Eur J Pharm Sci2004，22，： | 1 |
| 9 | Uptake and binding of cadmium,copper and zinc by Drosophila melanogaster larvae显示文摘 | Maroni G Watson D | 1985 | Insect Biochem1985，15，1： | 1 |
| 10 | Enteric-coating of pulsatile-release HPC capsules prepared by injection molding显示文摘 | Macchi E Zema L Maroni A | 2015 | EurJPharm Sci2015，70，： | 1 |
| 11 | Mechanism of chitosan adsorption on silica from aqueous solutions显示文摘 | Tiraferri A Maroni P Caro Rodnguez D | 2014 | Lang- muir2014，30，17： | 1 |
| 12 | Safety of local delivery of low-and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions 显示文摘 | HARVEY B MARONI J | 2002 | Human Gene TheraPy2002，13，： | 1 |
| 13 | Assessment through environmental and biological measurements of total daily exposure to volatile organic compounds of office workers in Milan, Italy显示文摘 | Carrer P Maroni M Alcini D | 2000 | Indoor Air2000，10，： | 1 |
| 14 | Factors Causing Malnutrition in Patients with Chronic Uremia显示文摘 | Mitch W E Maroni B J | 1999 | Am J Kidney Dis1999，33，1： | 1 |
| 15 | Developmental profile and tissue distribu-tion of alcohol dehydrogenase显示文摘 | Maroni G Stamey S C | 1983 | Dros Inf Serv1983，59，： | 1 |
| 16 | Neuropsychiatric syndromes in patients with systemic lupus erythematosus and primary Sjogren syndrome:a comparative population-based study显示文摘 | Harboe E Tjensvoll AB Maroni S | 2009 | Ann Rheum Dis2009，68，10： | 1 |
| 17 | Laparoscopic colonicresection for splenic flexure cancer: our experience 显示文摘 | Pisani CA Maroni N Sacchi M | 2015 | BMCGastroenterol2015，15，： | 1 |
| 18 | Indoor Air Quality,(Chapter2-Organic Pollutants)Air Quality Monograph显示文摘 | MARONI M SEIFERT B LINDVALL T | 1995 | Elsevier Science B V1995，3，： | 1 |
| 19 | In vitro and in vivo evaluation of an oral system for time and/or site-specific drug delivery显示文摘 | M E Sangalli A Maroni L Zema | 2001 | J Controlled Release2001，73，： | 1 |
| 20 | The usefulness of volume NT soRware in measuring the fetal nasal bone at 11 to 13 + 6 weeks of gestation显示文摘 | Nanni M Maroni E Bevini M | 2014 | Prenat Diagn2014，34，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员